Goldenwell Biotech, Inc. is an early-stage company focused on developing and selling dietary supplements, facing significant revenue declines and operating losses.

# Summary of Goldenwell Biotech, Inc.

## Company Overview
**Goldenwell Biotech, Inc.** was incorporated in the State of Nevada on August 20, 2019, and is focused on the research, development, production, and sales of healthcare and dietary supplement products. The company's primary office is located at 581 Boston Mills Road, Suite 300, Hudson, Ohio 44236.

## Business Operations
- **Products Offered:** Goldenwell Biotech has developed a range of dietary supplements including:
  - **JI MAI—Bovine Cardiac Vascular Active Peptide**
  - **Double Proline AG – 3D Active Collagen Peptide (DPAG)**
  - **Cartilage Peptide – Type II Collagen Peptide**
  - **Se Plus – Antioxidant Supplement**
  - **Sugar Master – Plant Extract Supplement**
  
- **Production Status:** The company has completed stages including marketing analysis, research and development, and production process planning. Production does not require special engineering for equipment, as all necessary machinery is available from existing manufacturers.

## Financial Information
- **Revenue:** For the fiscal year ended December 31, 2024, Goldenwell Biotech reported revenues of **$139**. This reflects a decline compared to **$1,836** for the fiscal year 2023.
- **Income:** The company incurred a **net loss** of **$131,498** in 2024, compared to a **net loss** of **$117,361** in 2023.
- **Cash and Cash Equivalents:** As of December 31, 2024, Goldenwell had **$49,404** in cash and cash equivalents.
- **Total Assets:** The total assets were reported at **$224,192**, while total liabilities stood at **$271,433**, resulting in stockholders' equity showing a deficit of **$47,241**.

## Employee and Customer Statistics
- **Employees:** Goldenwell Biotech currently has **3 non-employee officers**. The specifics regarding the total number of employees or customers are not detailed in the provided information.
- **Customers:** There is no specific data available regarding the number of customers served by the company.

## Summary
Goldenwell Biotech, Inc. is an early-stage company engaged in the nutraceutical field, focusing on dietary supplements with minimal revenue generation and regular operating losses. Given its current operations and financial situation, the company is in the process of establishing itself in the market while relying heavily on financing to continue its operations.

Goldenwell Biotech, Inc. is an emerging biotechnology firm specializing in nutraceuticals and dietary supplements, with a focus on health improvements and cardiovascular, joint, and skin health.

# Goldenwell Biotech, Inc. Overview

## Company Profile
- **Incorporation Date:** August 20, 2019
- **Location:** 581 Boston Mills Road, Suite 300, Hudson, Ohio 44236
- **Fiscal Year End:** December 31
- **Industry:** Nutraceuticals and Dietary Supplements
- **Employees:** 3 non-employee officers (no full-time employees)

## Business Operations
Goldenwell Biotech, Inc. specializes in the development, production, and sales of dietary supplements and health care products. The company holds exclusive license agreements for proprietary technologies used in its product formulations.

### License Agreements
1. **Australian Trefoil Health Technologies Pty Ltd**
   - Licensed technology and packaging designs for Sugar Master and DNA Repair products.
   - Agreement Term: Until November 15, 2025.

2. **Ji Lin JZY Biotech Inc.**
   - Licensed technology for product manufacturing.
   - Agreement Term: Until January 11, 2025.

Both agreements cover all territories except China, and the total consideration paid for these licenses was $20 (two separate agreements at $10 each).

### Product Offerings
The company has developed five products that are in various stages of development:
1. **JI MAI - Bovine Cardiac Vascular Active Peptide**
   - Focused on cardiovascular health with freeze-dried bovine heart peptides.

2. **Double Proline AG – 3D Active Collagen Peptide (DPAG)**
   - Aimed at skin health, leveraging collagen extracted from bovine sources.

3. **Cartilage Peptide - Type II Collagen Peptide**
   - A dietary supplement targeting joint health.

4. **Se Plus**
   - Contains L-Se-Methylselenocysteine with antioxidant properties targeting middle-aged and elderly individuals.

5. **Sugar Master**
   - Extracted herbal polypeptides aimed at glucose management.

### Financial Performance
- **Revenue:**
  - 2023: $2,340
  - 2022: $47,800

- **Net Loss:**
  - 2023: $116,895
  - 2022: $985,097

- **Cash and Cash Equivalents (as of December 31, 2023):** $54,231
- **Total Assets (as of December 31, 2023):** $228,057
- **Total Liabilities (as of December 31, 2023):** $143,334
- **Total Stockholders' Equity (as of December 31, 2023):** $84,723

### Market Position
- The company's shares are traded on the OTC Pink tier of the OTC Markets Group under the symbol [GWLL].
- As of March 29, 2024, the company has approximately 84 holders of record for its common stock, which totals 99,000,000 shares issued and outstanding.

### Future Outlook
Goldenwell Biotech intends to secure financing and construct manufacturing facilities, estimated to require approximately $5,000,000 and a one-year timeline from initiation to completion, to enhance commercial sales of its products. 

### Summary
Goldenwell Biotech, Inc. is an early-stage biotechnology firm focused on health supplements with products aimed at improving cardiovascular health, joint health, and skin health. The company is in a phase of transitioning from development to commercial sales, facing challenges related to financing and operational initiation.

GOLDENWELL BIOTECH, INC.

10-K / May 15, 2025

10-K / April 12, 2024

10-K / May 15, 2025

Summary of Goldenwell Biotech, Inc.

Company Overview

Business Operations

Financial Information

Employee and Customer Statistics

Summary